GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of genuine question about telehealth that I am slightly embarrassed to ask — 56 comments in the full submission. View in context.
844
c/compounding·submitted 1 year ago by u/ahmed_okafor

genuine question about telehealth that I am slightly embarrassed to ask

Regulatorybranch of 9 comments

genuine question about telehealth that I am slightly embarrassed to ask, and I want the answer with the reasoning attached rather than just the conclusion. The five questions worth asking before you commit to any compounded arrangement. Which facility, by name. Whether it is a 503A pharmacy or a 503B outsourcing…

Read the full submission and all 56 comments →

This branch

9 comments, started 1 year ago
u/quiet_moderatorMOD29 points·1 year ago

Removed the staff name. Facilities and clinics can be named here; individuals cannot.

replysharereportpermalink
[removed]19 points·1 year ago

[removed by moderator]

replysharereportpermalink
u/rekha_mwangi17 points·1 year ago

Asked for potency testing on the finished preparation. They had it. I had assumed they would not.

replysharereportpermalink
u/ahmed_okaforOP23 points·1 year ago

if a clinic will not name the facility, that is your answer

replysharereportpermalink
u/rt_shift_reggie8 points·1 year ago

do not assume the concentration matches the branded product

replysharereportpermalink
u/liver_enzyme_liz6 points·1 year ago

I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.

replysharereportpermalink
u/marit_laurent4 points·1 year ago

I would not read the price difference as a quality signal.

Agreed — and the follow-up question is what the beyond-use date is based on.

replysharereportpermalink
u/hassan_chowdhury3 points·1 year ago

shortage status changes and the whole arrangement changes with it

replysharereportpermalink
load more comments (1) →

← back to the whole thread

About c/compounding

Compounded GLP-1s as a supply route: the 503A/503B distinction, the shortage-list mechanics that made compounding legal and then didn't, state board rules, telehealth prescriber models, and what a compounding pharmacy will and will not tell you about its API source.

53kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/compounding rules
  1. Regulatory claims need a citation to the actual rule, notice or docket.
  2. No pharmacy referral codes. Naming a pharmacy is fine; recruiting for it is not.
  3. API source questions are on-topic and pharmacies dodging them is newsworthy.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.